Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01154062 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Pazopanib Tablets in Patients Who Have Neovascular Age-related Macular Degeneration
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT01154062 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 15 participants.
The verdict
NCT01154062, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
A study to evaluate pazopanib tablets in male and female adults of non-child bearing potential with subfoveal CNV due to neovascular AMD. The goal is to assess safety and how well the subjects tolerate the drug. The study will also look at how the body breaks down and metabolizes the drug. All subjects will start the study up to 8 days prior to receiving drug. Once started subjects will take one tablet each day for 28 days. A follow up visit will occur approximately 2 weeks after drug is stopped.
Interventions
- DRUG Pazopanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2010-08-16 |
| Est. Completion | 2011-04-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01154062
The ClinicalTrials.gov registry entry for NCT01154062 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pazopanib is the first listed.
NCT01154062 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01154062 about?
NCT01154062 is a clinical study titled "A Study to Evaluate Pazopanib Tablets in Patients Who Have Neovascular Age-related Macular Degeneration". A study to evaluate pazopanib tablets in male and female adults of non-child bearing potential with subfoveal CNV due to neovascular AMD. The goal is to assess safety and how well the subjects tolerate the drug. The study will also look at how the body breaks down and metabolizes the drug. All subje...
What is the current status of trial NCT01154062?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2010-08-16. Estimated completion is 2011-04-29.
What interventions are being tested in trial NCT01154062?
The interventions under investigation include: Pazopanib (DRUG).
Who is sponsoring clinical trial NCT01154062?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.